These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 34985992)

  • 21. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.
    Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
    Tian Y; Zhai X; Yan W; Zhu H; Yu J
    Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
    Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise.
    Jacobs F; Carnio S; De Stefanis P; Luciano A; Novello S
    Eur J Cancer; 2021 May; 149():114-116. PubMed ID: 33857885
    [No Abstract]   [Full Text] [Related]  

  • 28. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
    Ren S; Xiong X; You H; Shen J; Zhou P
    Front Immunol; 2021; 12():689132. PubMed ID: 34149730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].
    Zhang T; Li B
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):188-195. PubMed ID: 33819969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy.
    Shao C; Yang M; Pan Y; Xie D; Chen B; Ren S; Zhou C
    Front Immunol; 2021; 12():696749. PubMed ID: 34413851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature.
    Désage AL; Duruisseaux M; Lafitte C; Bayle-Bleuez S; Chouaid C; Fournel P; Pierret T
    Cancer Treat Rev; 2024 Sep; 129():102805. PubMed ID: 39111188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.
    Fan TW; Higashi RM; Song H; Daneshmandi S; Mahan AL; Purdom MS; Bocklage TJ; Pittman TA; He D; Wang C; Lane AN
    Elife; 2021 Aug; 10():. PubMed ID: 34406120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.
    Gelsomino F; Facchinetti F; Sisi M; Zielli T; Tiseo M; Ardizzoni A
    Immunotherapy; 2021 Apr; 13(5):363-369. PubMed ID: 33533279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.
    Zhou K; Li S; Zhao Y; Cheng K
    Front Immunol; 2023; 14():1127071. PubMed ID: 36845142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
    Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Small Cell Lung Cancer Metastatic Without Oncogenic Alterations.
    Frost N; Reck M
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432524. PubMed ID: 38669613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.